Company Encyclopedia
View More
name
Vivos Therapeutics
VVOS.US
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
385.64 B
VVOS.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care ServicesIndustry
Industry Ranking49/77
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-335.45%E
    • Profit Margin-98.76%E
    • Gross Margin58.04%B
  • Growth ScoreB
    • Revenue YoY18.76%B
    • Net Profit YoY-36.08%D
    • Total Assets YoY67.09%A
    • Net Assets YoY-66.97%E
  • Cash ScoreC
    • Cash Flow Margin-101.25%D
    • OCF YoY18.76%B
  • Operating ScoreB
    • Turnover0.84B
  • Debt ScoreE
    • Gearing Ratio90.13%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital

    Vivos Therapeutics, Inc. has secured a $2.1 million unsecured loan from Avondale Capital, LLC. The loan, under a Note Purchase Agreement dated December 5, 2025, provides Vivos with approximately $1.5 million in gross proceeds. The note is not convertible into common stock and bears no interest unless in default. Weekly payments start December 12, 2025, with prepayment options available. The loan is guaranteed by Vivos's subsidiary, Airway Integrated Management Company, LLC, and will be used for working capital and general corporate purposes.

    Reuters·
    US
    VVOS
    -1.90%
    Reuters·
    US
    VVOS
    -1.90%

    CEO Korenko Buys 100,000 ($6.2K) Of Vivos Inc [RDGL]

    Korenko Michael K Chief Executive Officer of Vivos Inc [RDGL] filed a Form 4 on November 20, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionPurchaseShares100,000Price$0.06Value$6,220Ending Holdings: 10,635,090 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    VVOS
    -1.90%
    Reuters·
    US
    VVOS
    -1.90%

    Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares

    Michael K. Korenko, CEO and President of Vivos Inc., has acquired common shares of the company. This event was reported through EDGAR by Vivos Inc. on November 20, 2025. The information is provided by Public Technologies using AI and is not financial advice.

    Reuters·
    US
    VVOS
    -1.90%
    Reuters·
    US
    VVOS
    -1.90%

    Vivos Therapeutics | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 6.783 M

    LB filings·
    US
    VVOS
    -1.90%
    LB filings·
    US
    VVOS
    -1.90%

    Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

    Vivos Therapeutics Inc. reported a 78% sequential revenue growth in Q3 2025, with a 76% increase year-over-year. This growth is attributed to a strategic shift from dental industry distribution to acquiring medical sleep practices, highlighted by acquiring The Sleep Center of Nevada in June 2025. Detailed financial results are available in their Form 10-Q filed with the SEC.

    Reuters·
    US
    VVOS
    -1.90%
    Reuters·
    US
    VVOS
    -1.90%
    © 2025 Longbridge｜Disclaimer